Ascendis Pharma A/S (NASDAQ:ASND) Shares Gap Up to $126.97

Ascendis Pharma A/S (NASDAQ:ASND)’s share price gapped up prior to trading on Monday . The stock had previously closed at $126.97, but opened at $137.01. Ascendis Pharma A/S shares last traded at $134.50, with a volume of 266,150 shares traded.

Analyst Ratings Changes

A number of brokerages recently weighed in on ASND. Wells Fargo & Company raised their target price on shares of Ascendis Pharma A/S from $260.00 to $262.00 and gave the company an “overweight” rating in a research note on Friday, May 3rd. TD Cowen upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating and raised their target price for the stock from $156.00 to $175.00 in a report on Tuesday, June 25th. JPMorgan Chase & Co. raised their target price on shares of Ascendis Pharma A/S from $167.00 to $170.00 and gave the stock an “overweight” rating in a report on Friday, May 3rd. Stifel Nicolaus began coverage on shares of Ascendis Pharma A/S in a report on Friday, May 31st. They issued a “buy” rating and a $200.00 price target on the stock. Finally, StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Thursday, May 23rd. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, Ascendis Pharma A/S currently has an average rating of “Moderate Buy” and an average target price of $179.00.

Ascendis Pharma A/S Trading Up 1.8 %

The stock has a 50 day moving average of $132.83 and a 200-day moving average of $139.00. The company has a market capitalization of $7.53 billion, a P/E ratio of -13.21 and a beta of 0.63.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC bought a new position in Ascendis Pharma A/S in the 4th quarter worth approximately $25,000. Private Ocean LLC bought a new position in Ascendis Pharma A/S in the 1st quarter worth approximately $36,000. Quadrant Capital Group LLC boosted its stake in Ascendis Pharma A/S by 90.4% in the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 151 shares during the period. EverSource Wealth Advisors LLC boosted its stake in Ascendis Pharma A/S by 37.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 91 shares during the period. Finally, Barometer Capital Management Inc. bought a new position in Ascendis Pharma A/S in the 4th quarter worth approximately $126,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.